Memo - Magazine of European Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Lymphomas off the beaten track
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 1, 2023 Category: Cancer & Oncology Source Type: research

Colorectal cancer special, part 1
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 1, 2023 Category: Cancer & Oncology Source Type: research

Best of hematology —2021
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 1, 2023 Category: Cancer & Oncology Source Type: research

Radiooncology and nuclear medicine
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 1, 2023 Category: Cancer & Oncology Source Type: research

Austrian Society for Hematology and Medical Oncology (OeGHO) spring meeting 2023
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 1, 2023 Category: Cancer & Oncology Source Type: research

Efficacy of dual checkpoint-blockade in solid tumors, part 1
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 1, 2023 Category: Cancer & Oncology Source Type: research

Barriers to patient access of CAR T cell therapies in Austria
This report discusses potential barriers that may impede current patient access to CAR T cell therapy and provides recommendations for systemic solutions to address these barriers and improve the CAR T access situation in Austria. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 31, 2023 Category: Cancer & Oncology Source Type: research

Update on systemic therapy for clear cell renal cell carcinoma
SummaryThe treatment landscape of advanced and metastatic renal cell carcinoma (RCC) has changed fundamentally over the last two decades with the introduction of tyrosine kinase inhibitors (TKIs) in 2005 and immune checkpoint inhibitors (ICIs) about 10 years later, both demonstrating significantly improved overall survival (OS) rates across all RCC risk categories. Currently, combination therapies represent the standard-of-care in the first-line setting of clear cell RCC in almost all cases. In this short review article, the most recent therapeu tic advances in early and advanced stage of clear cell RCC are summarized. (...
Source: Memo - Magazine of European Medical Oncology - January 24, 2023 Category: Cancer & Oncology Source Type: research

News on Peripheral T-cell lymphoma
SummaryPeripheral T ‑cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies. Brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV+CHP, anti-CD30) is indicated as first-line treatment in the subgroup anaplastic large cell lymphoma (ALCL). Romidepsin plus cyclophosphamide, d oxorubicin, vincristine, and prednisone (Ro-CHOP) is inferior to CHOP in PTCL; however, the subtype angioimmunoblastic T‑cell lymphoma (AITL) might favor Ro-CHOP. An increase of survival after consolidation with autologous stem cell transplantation (ASCT) in first line was found in a retrospective analysis...
Source: Memo - Magazine of European Medical Oncology - January 19, 2023 Category: Cancer & Oncology Source Type: research

Cutaneous lymphomas —fast facts about an orphan disease—a short review
SummaryCutaneous lymphomas are a rare group of primary skin lymphoproliferative disorders, divided into T and B cell lymphomas. They differ substantially in clinical course and therapy. The two main subtypes of primary cutaneous T‑cell lymphomas include mycosis fungoides, which is the most common, and Sézary syndrome, the ra re leukemic variant. Skin lesions seen in mycosis fungoides patients are erythematous patches, plaques, or tumors. Most patients remain at patch/plaque (early) stage, while some progress to tumor (advanced) stage during their clinical course. Sézary syndrome is characterized by erythroderma and...
Source: Memo - Magazine of European Medical Oncology - January 13, 2023 Category: Cancer & Oncology Source Type: research